

Cumulative (JPYmn)	FY03/21				FY03/22				FY03/23		FY03/23			
	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	% of Est.	1H Est.	% of Est.	FY Est.
Sales	25,162	51,045	78,167	104,257	25,914	52,169	79,868	106,685	26,299	53,340	99.8%	53,460	48.5%	110,000
YoY	-1.7%	-2.2%	-1.0%	-0.9%	3.0%	2.2%	2.2%	2.3%	1.5%	2.2%				3.1%
Gross profit	9,704	20,502	31,665	42,412	10,738	21,861	33,443	44,429	11,062	22,315				
YoY	-1.4%	3.4%	4.8%	5.5%	10.7%	6.6%	5.6%	4.8%	3.0%	2.1%				
Gross profit margin	38.6%	40.2%	40.5%	40.7%	41.4%	41.9%	41.9%	41.6%	42.1%	41.8%				
SG&A expenses	9,765	19,147	28,892	38,982	10,071	19,999	30,379	40,576	10,713	21,215				
YoY	2.7%	0.7%	-0.4%	1.0%	3.1%	4.4%	5.1%	4.1%	6.4%	6.1%				
SG&A ratio	38.8%	37.5%	37.0%	37.4%	38.9%	38.3%	38.0%	38.0%	40.7%	39.8%				
Operating profit	-61	1,355	2,773	3,429	667	1,862	3,063	3,852	348	1,099	98.1%	1,120	31.4%	3,500
YoY	-	70.2%	125.8%	112.3%	-	37.4%	10.5%	12.3%	-47.8%	-41.0%				-9.1%
Operating profit margin	-	2.7%	3.5%	3.3%	2.6%	3.6%	3.8%	3.6%	1.3%	2.1%				3.2%
Recurring profit	-62	1,397	2,770	3,479	935	2,235	3,485	4,313	392	1,242	98.6%	1,260	33.6%	3,700
YoY	-	78.2%	129.3%	123.0%	-	60.0%	25.8%	24.0%	-58.1%	-44.4%				-14.2%
Recurring profit margin	-	2.7%	3.5%	3.3%	3.6%	4.3%	4.4%	4.0%	1.5%	2.3%				3.4%
Net income	-201	578	2,013	2,198	583	1,431	2,144	2,394	91	502	85.1%	590	28.7%	1,750
YoY	-	165.1%	517.5%	-	-	147.6%	6.5%	8.9%	-84.4%	-64.9%				-26.9%
Net margin	-	1.1%	2.6%	2.1%	2.2%	2.7%	2.7%	2.2%	0.3%	0.9%				1.6%

Quarterly (JPYmn)	FY03/21				FY03/22				FY03/23	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Sales	25,162	25,883	27,122	26,090	25,914	26,255	27,699	26,817	26,299	27,041
YoY	-1.7%	-2.8%	1.5%	-0.8%	3.0%	1.4%	2.1%	2.8%	1.5%	3.0%
Gross profit	9,704	10,798	11,163	10,747	10,738	11,123	11,582	10,986	11,062	11,253
YoY	-1.4%	8.2%	7.3%	7.6%	10.7%	3.0%	3.8%	2.2%	3.0%	1.2%
Gross profit margin	38.6%	41.7%	41.2%	41.2%	41.4%	42.4%	41.8%	41.0%	42.1%	41.6%
SG&A expenses	9,765	9,382	9,745	10,090	10,071	9,928	10,380	10,197	10,713	10,502
YoY	2.7%	-1.4%	-2.3%	5.1%	3.1%	5.8%	6.5%	1.1%	6.4%	5.8%
SG&A ratio	38.8%	36.2%	35.9%	38.7%	38.9%	37.8%	37.5%	38.0%	40.7%	38.8%
Operating profit	-61	1,416	1,418	656	667	1,195	1,201	789	348	751
YoY	-	206.5%	228.2%	69.5%	-	-15.6%	-15.3%	20.3%	-47.8%	-37.2%
Operating profit margin	-	5.5%	5.2%	2.5%	2.6%	4.6%	4.3%	2.9%	1.3%	2.8%
Recurring profit	-62	1,459	1,373	709	935	1,300	1,250	828	392	850
YoY	-	216.5%	223.8%	101.4%	-	-10.9%	-9.0%	16.8%	-58.1%	-34.6%
Recurring profit margin	-	5.6%	5.1%	2.7%	3.6%	5.0%	4.5%	3.1%	1.5%	3.1%
Net income	-201	779	1,435	185	583	848	713	250	91	411
YoY	-	543.8%	1,228.7%	-	-	8.9%	-50.3%	35.1%	-84.4%	-51.5%
Net margin	-	3.0%	5.3%	0.7%	2.2%	3.2%	2.6%	0.9%	0.3%	1.5%

Source: Shared Research based on company data

Note: Figures may differ from company materials due to differences in rounding methods.

## Quarterly results

By segment (cumulative) (JPYmn)	FY03/21				FY03/22				FY03/23	
	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2
Sales	25,162	51,045	78,167	104,257	25,914	52,169	79,868	106,685	26,299	53,340
YoY	-1.7%	-2.2%	-1.0%	-0.9%	3.0%	2.2%	2.2%	2.3%	1.5%	2.2%
Community Pharmacy Network	23,922	48,539	74,368	99,214	24,657	49,663	75,986	101,457	25,045	50,792
YoY	-1.2%	-1.5%	-0.4%	-0.4%	3.1%	2.3%	2.2%	2.3%	1.6%	2.3%
% of total	94.5%	94.5%	94.6%	94.6%	94.6%	94.6%	94.5%	94.5%	94.5%	94.5%
Leasing and Facility-related	723	1,438	2,194	2,940	739	1,536	2,461	3,326	794	1,673
YoY	-4.9%	-21.4%	-17.5%	-14.2%	2.2%	6.8%	12.2%	13.1%	7.4%	8.9%
% of total	2.9%	2.8%	2.8%	2.8%	2.8%	2.9%	3.1%	3.1%	3.0%	3.1%
Meal Catering	612	1,248	1,874	2,474	586	1,166	1,752	2,322	573	1,135
YoY	-16.2%	-13.0%	-11.9%	-11.5%	-4.2%	-6.6%	-6.5%	-6.1%	-2.2%	-2.7%
% of total	2.4%	2.4%	2.4%	2.4%	2.2%	2.2%	2.2%	2.2%	2.2%	2.1%
Other	51	110	171	229	74	152	232	305	77	151
YoY	34.2%	39.2%	40.2%	38.8%	45.1%	38.2%	35.7%	33.2%	4.1%	-0.7%
% of total	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Segment sales adjustments	-154	-292	-442	-601	-143	-350	-563	-727	-190	-412
Operating profit	-61	1,355	2,773	3,429	667	1,862	3,063	3,852	348	1,099
YoY	-	70.2%	125.8%	112.3%	-	37.4%	10.5%	12.3%	-47.8%	-41.0%
Community Pharmacy Network	434	2,369	4,329	5,703	1,202	2,885	4,663	6,117	1,014	2,384
YoY	-47.4%	36.5%	56.6%	52.4%	177.0%	21.8%	7.7%	7.3%	-15.6%	-17.4%
Operating profit margin	1.8%	4.9%	5.8%	5.7%	4.9%	5.8%	6.1%	6.0%	4.0%	4.7%
Leasing and Facility-related	6	16	34	32	-2	32	53	39	-43	-65
YoY	-	-76.5%	-49.3%	-28.9%	-	100.0%	55.9%	21.9%	-	-
Operating profit margin	0.8%	1.1%	1.5%	1.1%	-	2.1%	2.2%	1.2%	-	-
Meal Catering	-19	-13	-2	-21	-1	1	7	1	-11	-33
YoY	-	-	-	-	-	-	-	-	-	-
Operating profit margin	-	-	-	-	-	0.1%	0.4%	0.0%	-	-
Other	-11	-13	-17	-31	-7	-12	-10	-12	-2	-10
YoY	-	-	-	-	-	-	-	-	-	-
Operating profit margin	-	-	-	-	-	-	-	-	-	-
Segment profit adjustments	-472	-1,003	-1,569	-2,253	-523	-1,043	-1,650	-2,293	-608	-1,175


Sales	FY03/21				FY03/22				FY03/23	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Sales	25,162	25,883	27,122	26,090	25,914	26,255	27,699	26,817	26,299	27,041
YoY	-1.7%	-2.8%	1.5%	-0.8%	3.0%	1.4%	2.1%	2.8%	1.5%	3.0%
Community Pharmacy Network	23,922	24,617	25,829	24,846	24,657	25,006	26,323	25,471	25,045	25,747
YoY	-1.2%	-1.8%	-1.9%	-0.5%	3.1%	1.6%	1.9%	2.5%	1.6%	3.0%
% of total	94.5%	94.6%	94.7%	94.7%	93.5%	94.5%	94.3%	94.4%	96.8%	94.4%
Leasing and Facility-related	723	715	756	746	739	797	925	865	794	879
YoY	-4.9%	-33.1%	-8.9%	-2.6%	2.2%	11.5%	22.4%	16.0%	7.4%	10.3%
% of total	2.9%	2.7%	2.8%	2.8%	2.8%	3.0%	3.3%	3.2%	3.1%	3.2%
Meal Catering	612	636	626	600	586	580	586	570	573	562

YoY	-16.2%	-9.7%	-9.8%	-10.3%	-4.2%	-8.8%	-6.4%	-5.0%	-2.2%	-3.1%
% of total	2.4%	2.4%	2.3%	2.3%	2.2%	2.2%	2.1%	2.1%	2.2%	2.1%
Other	51	59	61	58	74	78	80	73	77	74
YoY	34.2%	43.9%	41.9%	34.9%	45.1%	32.2%	31.1%	25.9%	4.1%	-5.1%
% of total	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Segment sales adjustments	-154	-138	-150	-159	-463	-207	-213	-164	413	-222
<b>Operating profit</b>	<b>-61</b>	<b>1,416</b>	<b>1,418</b>	<b>656</b>	<b>667</b>	<b>1,195</b>	<b>1,201</b>	<b>789</b>	<b>348</b>	<b>751</b>
YoY	-	206.5%	228.2%	69.5%	-	-15.6%	-15.3%	20.3%	-47.8%	-37.2%
Community Pharmacy Network	434	1,935	1,960	1,374	1,202	1,683	1,778	1,454	1,014	1,370
YoY	-47.4%	112.4%	90.7%	40.3%	177.0%	-13.0%	-9.3%	5.8%	-15.6%	-18.6%
Operating profit margin	1.8%	7.9%	7.6%	5.5%	4.9%	6.7%	6.8%	5.7%	4.0%	5.3%
Leasing and Facility-related	6	10	18	-2	-2	34	21	-14	-43	-22
YoY	-	-86.8%	-	-	-	240.0%	16.7%	-	-	-
Operating profit margin	0.8%	1.4%	2.4%	-	-	4.3%	2.3%	-	-	-
Meal Catering	-19	6	11	-19	-1	2	6	-6	-11	-22
YoY	-	-	-	-	-	-66.7%	-45.5%	-	-	-
Operating profit margin	-	0.9%	1.8%	-	-	0.3%	1.0%	-	-	-
Other	-11	-2	-4	-14	-7	-5	2	-2	-2	-8
YoY	-	-	-	-	-	-	-	-	-	-
Operating profit margin	-	-	-	-	-	-	2.5%	-	-	-
Segment profit adjustments	-472	-531	-566	-684	-523	-520	-607	-643	-608	-567

Source: Shared Research based on company data

Note: Figures may differ from company materials due to differences in rounding methods.

## (Reference) Former Pharmaceuticals Network segment sales




Source: Shared Research based on company data

Notes: Undisclosed from Q2 FY03/19

The former Pharmaceuticals Network segment was integrated into the new Community Pharmacy Network segment from FY03/20

## Quarterly trends in prescription volume and price per prescription (drug price + technical fees; Community Pharmacy business [former Dispensing Pharmacy business]; all stores)



Source: Shared Research based on company data

Note: NHI drug price and dispensing fee revisions were put into effect on April 1, 2014, April 1, 2016, and April 1, 2018.

## Number of network members by region

Area	Directly operated pharmacies	Affiliates	Total
Hokkaido	123	207	330
Tohoku	24	541	565
Kanto and Koshinetsu	99	2,437	2,536
Tokai and Hokuriku	44	1,342	1,386
Kinki	53	1,248	1,301
Chugoku and Shikoku	21	826	847
Kyushu and Okinawa	63	1,145	1,208
<b>Total</b>	<b>427</b>	<b>7,746</b>	<b>8,173</b>

Source: Shared Research based on company data (as of September 30, 2022)

## 1H FY03/23 results (out November 7, 2022)

### Overview

1H FY03/23 (April–September 2022) earnings results

- Sales: JPY53.3bn (+2.2% YoY)
- Operating profit: JPY1.1bn (-41.0% YoY)
- Recurring profit: JPY1.2bn (-44.4% YoY)
- Net income attributable to owners of the parent: JPY502mn (-64.9% YoY)

### Operating results and business conditions

Sales rose 2.2% YoY on the back of higher sales in the mainstay Community Pharmacy Network segment. In the Pharmaceutical Network Business, the number of new network members remained strong. In the Community Pharmacy business, the prescription unit price fell due to the impact of the NHI drug price and dispensing fee revisions, but the opening of new stores and acquisition of stores contributed to earnings.

Operating profit fell 41.0% YoY. Although the Pharmaceutical Network business posted higher profits, earnings were weighed down in the Community Pharmacy business by the impact of the NHI drug price and dispensing fee revisions and increased labor expenses accompanying efforts to strengthen interpersonal services.

### Segment results

1H FY03/23 results by segment were as follows.

## Community Pharmacy Network

- Segment sales: JPY50.8bn (+2.3% YoY; including intra-group sales and transfers between segments, same applies below)
- Segment profit: JPY2.4bn (-17.4% YoY)
- This is a new segment that integrates the former Pharmaceuticals Network business, the Dispensing Pharmacy business, and the manufacture and market pharmaceuticals business (mainly Feldsenf Pharma) previously included in Other. A digital shift business that utilizes instant messaging app LINE was added to the segment from FY03/21.

### Community Pharmacy

The prescription unit price fell due to the impact of the NHI drug price and dispensing fee revisions, but the prescription count rose on the back of the contribution of stores newly opened and acquired. During 1H FY03/23, the company opened four community pharmacies, including three inside medical malls. As of September 30, 2022, the company had 427 community pharmacies, one care plan center, and nine cosmetics/drug stores.

### Pharmaceuticals Network

The number of new network members continued to grow steadily amid rising demand for business efficiency at pharmacies as pharmacists further concentrated on interpersonal work due to the impact of dispensing fee revisions. As of September 30, 2022, pharmaceutical network members totaled 8,173 (an increase of 772 from March 31, 2022), comprising 427 directly operated pharmacies and 7,746 affiliates.

### Manufacture and Market Pharmaceuticals

In this business, the company group aims to provide a stable supply of good-quality, low-priced generic drugs. The company offered 85 products (42 ingredients) as of September 30, 2022, and supplied these to 1,886 general network affiliates (an increase of 188 from March 31, 2022).

### Digital Shift

The company established subsidiary PharmaShift Co., Ltd. on October 1, 2020, to create a “new pharmaceutical platform” for the digital age. In March 2021 the subsidiary launched the “Tsunagaru Pharmacy” service utilizing its official LINE account. As of end-September 2022, the number of pharmacies using the service was 2,332 (an increase of 1,421 from March 31, 2022) while 2,886 had placed orders for the service use (an increase of 1,223 from March 31, 2022).

## Leasing and Facility-related

- Segment sales: JPY1.7bn (+8.9% YoY)
- Segment loss: JPY65mn (versus profit of JPY32mn in 1H FY03/22)

### Operating conditions of serviced elderly housing facilities

Segment sales rose 7.4% YoY, as property leasing revenue was generally strong and orders for construction projects increased. However, the segment posted an operating loss due to increased advertising expenses accompanying aggressive sales promotion activities for the Wisteria serviced residences for the elderly and support services for physicians opening their own practices. As of end-September 2022, the company reported stable occupancy rates at three of its five properties (the overall occupancy rate at the five serviced residences for the elderly stood at 80.6%), while for the remaining two, at Wisteria Senri-Chuo it reported an occupancy rate of 69.5% (with 57 out of 82 units occupied), and at Wisteria Minami Ichijo it reported an occupancy rate of 69.0% (with 80 out of 116 units occupied).

## Meal Catering

- Segment sales: JPY1.1bn (-2.7% YoY)
- Segment loss: JPY33mn (versus profit of JPY1mn in 1H FY03/22)

### Lower sales and operating loss

In 1H FY03/23, sales decreased along with the decline in the number of meals supplied due to the COVID-19 pandemic, and a loss followed lower gross profit margin due to higher purchase prices.

## Other (mostly home-visit nursing care)

- Segment sales: JPY151mn (-0.7% YoY)

- Segment loss: JPY10mn (versus a loss of JPY12mn in 1H FY03/22)

## Company forecast for FY03/23

### Recent performance and FY03/23 company forecast

(JPYmn)	FY03/21			FY03/22			FY03/23		
	1H Act.	2H Act.	FY Act.	1H Act.	2H Act.	FY Act.	1H Act.	2H Est.	FY Est.
<b>Sales</b>	<b>51,045</b>	<b>53,212</b>	<b>104,257</b>	<b>52,169</b>	<b>54,516</b>	<b>106,685</b>	<b>53,340</b>	<b>56,660</b>	<b>110,000</b>
YoY	-2.2%	0.4%	-0.9%	2.2%	2.5%	2.3%	2.2%	3.9%	3.1%
Cost of sales	30,542	31,303	61,845	30,307	31,949	62,256	31,024		
<b>Gross profit</b>	<b>20,502</b>	<b>21,910</b>	<b>42,412</b>	<b>21,861</b>	<b>22,568</b>	<b>44,429</b>	<b>22,315</b>		
Gross profit margin	40.2%	41.2%	40.7%	41.9%	41.4%	41.6%	41.8%		
SG&A expenses	19,147	19,835	38,982	19,999	20,577	40,576	21,215		
SG&A ratio	37.5%	37.3%	37.4%	38.3%	37.7%	38.0%	39.8%		
<b>Operating profit</b>	<b>1,355</b>	<b>2,074</b>	<b>3,429</b>	<b>1,862</b>	<b>1,990</b>	<b>3,852</b>	<b>1,099</b>	<b>2,401</b>	<b>3,500</b>
YoY	70.2%	153.2%	112.3%	37.4%	-4.1%	12.3%	-41.0%	20.7%	-9.1%
Operating profit margin	2.7%	3.9%	3.3%	3.6%	3.7%	3.6%	2.1%	4.2%	3.2%
<b>Recurring profit</b>	<b>1,397</b>	<b>2,082</b>	<b>3,479</b>	<b>2,235</b>	<b>2,078</b>	<b>4,313</b>	<b>1,242</b>	<b>2,458</b>	<b>3,700</b>
YoY	78.2%	168.3%	123.0%	60.0%	-0.2%	24.0%	-44.4%	18.3%	-14.2%
Recurring profit margin	2.7%	3.9%	3.3%	4.3%	3.8%	4.0%	2.3%	4.3%	3.4%
<b>Net income</b>	<b>578</b>	<b>1,620</b>	<b>2,198</b>	<b>1,431</b>	<b>963</b>	<b>2,394</b>	<b>502</b>	<b>1,248</b>	<b>1,750</b>
YoY	165.1%	-	-	147.6%	-40.6%	8.9%	-64.9%	29.6%	-26.9%
Net margin	1.1%	3.0%	2.1%	2.7%	1.8%	2.2%	0.9%	2.2%	1.6%

Source: Shared Research based on company data

Note: Figures may differ from company materials due to differences in rounding methods.

# About Shared Research Inc.

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <https://sharedresearch.jp>.

## Contact Details

Company name

**Shared Research Inc.**

Phone

**+81 (0)3 5834-8787**

Address

**3-31-12 Sendagi Bunkyo-ku Tokyo, Japan**

Email

**[info@sharedresearch.jp](mailto:info@sharedresearch.jp)**

Website

**<https://sharedresearch.jp>**

## Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report. The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer: The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion from us that could influence investment decisions in the company, such an opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.